Stephanie L Pugh1, Joseph P Rodgers2, Jennifer Moughan2, Roseann Bonanni2, Jaskaran Boparai3, Ronald C Chen4, James J Dignam5, Deborah W Bruner6. 1. NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, PA, USA. pughs@nrgoncology.org. 2. NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, PA, USA. 3. NRG Oncology Operations Center, American College of Radiology, Philadelphia, PA, USA. 4. University of Kansas, Kansas City, KS, USA. 5. NRG Oncology Statistics and Data Management Center, University of Chicago, Chicago, IL, USA. 6. Emory University Hospital/Winship Cancer Institute, Atlanta, GA, USA.
Abstract
PURPOSE: NRG Oncology, part of the National Cancer Institute's National Clinical Trials Network, took efforts to increase patient-reported outcome measures (PROMs) completion and institutional data submission rates within clinical trials. Lack of completion diminishes power to draw conclusions and can be a waste of resources. It is hypothesized that trials with automatic email reminders and past due notifications will have PROM forms submitted more timely with higher patient completion. METHODS: Automatic emails sent to the research associate were added to selected NRG Oncology trials. Comparisons between trials with and without automatic emails were analyzed using Chi-square tests with respect to patient completion and timeliness of form submission rates. Multivariable analyses were conducted using repeated measures generalized estimating equations. If PROMs were not completed, a form providing the reason why was submitted and counted towards form submission. RESULTS: For both disease sites, form submission was significantly higher within 1 month of the form's due date for the studies with automatic emails vs. those without (prostate: 79.7% vs. 75.7%, p < 0.001; breast: 59.2% vs. 31.3%, p < 0.001). No significant differences in patient completion were observed between the breast trials. The prostate trial with automatic emails had significantly higher patient completion but this result was not confirmed in the multivariable analysis. CONCLUSIONS: Although patient completion rates were higher on trials with automatic emails, there may be confounding factors requiring future study. The automatic emails appeared to have increased the timeliness of form submission, thus supporting their continued use on NRG Oncology trials.
PURPOSE: NRG Oncology, part of the National Cancer Institute's National Clinical Trials Network, took efforts to increase patient-reported outcome measures (PROMs) completion and institutional data submission rates within clinical trials. Lack of completion diminishes power to draw conclusions and can be a waste of resources. It is hypothesized that trials with automatic email reminders and past due notifications will have PROM forms submitted more timely with higher patient completion. METHODS: Automatic emails sent to the research associate were added to selected NRG Oncology trials. Comparisons between trials with and without automatic emails were analyzed using Chi-square tests with respect to patient completion and timeliness of form submission rates. Multivariable analyses were conducted using repeated measures generalized estimating equations. If PROMs were not completed, a form providing the reason why was submitted and counted towards form submission. RESULTS: For both disease sites, form submission was significantly higher within 1 month of the form's due date for the studies with automatic emails vs. those without (prostate: 79.7% vs. 75.7%, p < 0.001; breast: 59.2% vs. 31.3%, p < 0.001). No significant differences in patient completion were observed between the breast trials. The prostate trial with automatic emails had significantly higher patient completion but this result was not confirmed in the multivariable analysis. CONCLUSIONS: Although patient completion rates were higher on trials with automatic emails, there may be confounding factors requiring future study. The automatic emails appeared to have increased the timeliness of form submission, thus supporting their continued use on NRG Oncology trials.
Entities:
Keywords:
Delinquent data; Form submission; Neurocognitive testing; Patient compliance; Patient-reported outcomes; Quality of life
Authors: Eva Maria Gamper; Virginie Nerich; Monika Sztankay; Caroline Martini; Johannes M Giesinger; Lorenza Scarpa; Sabine Buxbaum; Martin Jeller; Bernhard Holzner; Irene Virgolini Journal: Value Health Date: 2017-03-06 Impact factor: 5.725
Authors: Paul D Brown; Stephanie Pugh; Nadia N Laack; Jeffrey S Wefel; Deepak Khuntia; Christina Meyers; Ali Choucair; Sherry Fox; John H Suh; David Roberge; Vivek Kavadi; Soren M Bentzen; Minesh P Mehta; Deborah Watkins-Bruner Journal: Neuro Oncol Date: 2013-08-16 Impact factor: 12.300
Authors: Claire F Snyder; Neil K Aaronson; Ali K Choucair; Thomas E Elliott; Joanne Greenhalgh; Michele Y Halyard; Rachel Hess; Deborah M Miller; Bryce B Reeve; Maria Santana Journal: Qual Life Res Date: 2011-11-03 Impact factor: 4.147
Authors: Himanshu R Lukka; Stephanie L Pugh; Deborah W Bruner; Jean-Paul Bahary; Colleen A F Lawton; Jason A Efstathiou; Rajat J Kudchadker; Lee E Ponsky; Samantha A Seaward; Ian S Dayes; Darindra D Gopaul; Jeff M Michalski; Guila Delouya; Irving D Kaplan; Eric M Horwitz; Mack Roach; Wayne H Pinover; David C Beyer; John O Amanie; Howard M Sandler; Lisa A Kachnic Journal: Int J Radiat Oncol Biol Phys Date: 2018-06-18 Impact factor: 7.038
Authors: Paul D Brown; Paul A Decker; Teresa A Rummans; Matthew M Clark; Marlene H Frost; Karla V Ballman; Robert M Arusell; Jan C Buckner Journal: Am J Clin Oncol Date: 2008-04 Impact factor: 2.339
Authors: William A Hall; Snehal Deshmukh; Deborah W Bruner; Jeff M Michalski; James A Purdy; Walter Bosch; Jean-Paul Bahary; Maltibehn P Patel; Matthew B Parliament; Michael I Lock; Harold Y Lau; Luis Souhami; Scot A Fisher; Young Kwok; Michael J Seider; Eric Vigneault; Seth A Rosenthal; Gary S Gustafson; Hiram A Gay; Stephanie L Pugh; Howard M Sandler; Benjamin Movsas Journal: Int J Radiat Oncol Biol Phys Date: 2022-01-01 Impact factor: 7.038